Literature DB >> 30187294

Trusting the Results of Model-Based Economic Analyses: Is there a Pragmatic Validation Solution?

Salah Ghabri1, Matt Stevenson2, Jörgen Möller3, J Jaime Caro4,5,6,7.   

Abstract

Models have become a nearly essential component of health technology assessment. This is because the efficacy and safety data available from clinical trials are insufficient to provide the required estimates of impact of new interventions over long periods of time and for other populations and subgroups. Despite more than five decades of use of these decision-analytic models, decision makers are still often presented with poorly validated models and thus trust in their results is impaired. Among the reasons for this vexing situation are the artificial nature of the models, impairing their validation against observable data, the complexity in their formulation and implementation, the lack of data against which to validate the model results, and the challenges of short timelines and insufficient resources. This article addresses this crucial problem of achieving models that produce results that can be trusted and the resulting requirements for validation and transparency, areas where our field is currently deficient. Based on their differing perspectives and experiences, the authors characterize the situation and outline the requirements for improvement and pragmatic solutions to the problem of inadequate validation.

Entities:  

Mesh:

Year:  2019        PMID: 30187294     DOI: 10.1007/s40273-018-0711-9

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  5 in total

Review 1.  An Educational Review About Using Cost Data for the Purpose of Cost-Effectiveness Analysis.

Authors:  Matthew Franklin; James Lomas; Simon Walker; Tracey Young
Journal:  Pharmacoeconomics       Date:  2019-05       Impact factor: 4.981

2.  Cooking Up a Transparent Model Following a DICE Recipe.

Authors:  Jörgen Möller
Journal:  Pharmacoeconomics       Date:  2019-11       Impact factor: 4.981

Review 3.  Systematic Literature Review of Economic Evaluations of Biological Treatment Sequences for Patients with Moderate to Severe Rheumatoid Arthritis Previously Treated with Disease-Modifying Anti-rheumatic Drugs.

Authors:  Salah Ghabri; Laurent Lam; François Bocquet; Hans-Martin Spath
Journal:  Pharmacoeconomics       Date:  2020-05       Impact factor: 4.981

4.  Four Aspects Affecting Health Economic Decision Models and Their Validation.

Authors:  Talitha Feenstra; Isaac Corro-Ramos; Dominique Hamerlijnck; George van Voorn; Salah Ghabri
Journal:  Pharmacoeconomics       Date:  2021-12-16       Impact factor: 4.981

Review 5.  Quantitative Evidence Synthesis Methods for the Assessment of the Effectiveness of Treatment Sequences for Clinical and Economic Decision Making: A Review and Taxonomy of Simplifying Assumptions.

Authors:  Ruth A Lewis; Dyfrig Hughes; Alex J Sutton; Clare Wilkinson
Journal:  Pharmacoeconomics       Date:  2020-11-26       Impact factor: 4.981

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.